Cost Management Insights: SG&A Expenses for AstraZeneca PLC and Geron Corporation

Navigating Cost Management: AstraZeneca vs. Geron Corporation

In the ever-evolving pharmaceutical landscape, effective cost management is crucial. AstraZeneca PLC and Geron Corporation, two prominent players, showcase contrasting strategies in managing Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, AstraZeneca's SG&A expenses surged by approximately 35%, peaking in 2022. This reflects their aggressive expansion and investment in R&D. In contrast, Geron Corporation's SG&A expenses, though significantly lower, increased by over 300% during the same period, indicating a strategic shift towards growth and market penetration.

AstraZeneca's expenses, consistently over 500 times higher than Geron's, highlight their global scale and operational complexity. Meanwhile, Geron's leaner structure allows for nimble adjustments in a competitive market. Understanding these dynamics offers valuable insights into how pharmaceutical giants balance growth and efficiency.